Joanne Hama

Array ( [id] => 17533699 [patent_doc_number] => 20220112308 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-14 [patent_title] => KRAS SPECIFIC ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/243129 [patent_app_country] => US [patent_app_date] => 2021-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63144 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -73 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17243129 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17036738 [patent_doc_number] => 20210253696 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => BIVALENT CHIMERIC ENGULFMENT RECEPTORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/154959 [patent_app_country] => US [patent_app_date] => 2021-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21878 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17154959 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16885428 [patent_doc_number] => 20210171623 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => HUMAN ANTIBODY SPECIFIC FOR INTERLEUKIN-1ALPHA [patent_app_type] => utility [patent_app_number] => 17/154137 [patent_app_country] => US [patent_app_date] => 2021-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7011 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17154137 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16946620 [patent_doc_number] => 20210205311 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors [patent_app_type] => utility [patent_app_number] => 17/138485 [patent_app_country] => US [patent_app_date] => 2020-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32412 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17138485 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16778049 [patent_doc_number] => 20210115127 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-22 [patent_title] => ANTI-IL-27 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/033469 [patent_app_country] => US [patent_app_date] => 2020-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56874 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17033469 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17913258 [patent_doc_number] => 20220315653 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-06 [patent_title] => BISPECIFIC BINDING AGENT THAT BINDS TO CD117/c-KIT AND CD3 [patent_app_type] => utility [patent_app_number] => 17/640412 [patent_app_country] => US [patent_app_date] => 2020-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12453 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17640412 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16671404 [patent_doc_number] => 20210060167 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-04 [patent_title] => CARBON MONOXIDE-RELEASING MOLECULE CONJUGATES AND RELATED COMPOSITIONS AND METHODS [patent_app_type] => utility [patent_app_number] => 17/004522 [patent_app_country] => US [patent_app_date] => 2020-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10853 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17004522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17882758 [patent_doc_number] => 20220298235 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-22 [patent_title] => ANTI-HUMAN P40 PROTEIN DOMAIN ANTIBODY AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/631797 [patent_app_country] => US [patent_app_date] => 2020-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24209 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17631797 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16596707 [patent_doc_number] => 20210023238 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-28 [patent_title] => TRIPTOLIDE ANTIBODY CONJUGATES [patent_app_type] => utility [patent_app_number] => 16/937483 [patent_app_country] => US [patent_app_date] => 2020-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31795 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16937483 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16762388 [patent_doc_number] => 20210107969 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-15 [patent_title] => MOLECULES, COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/925068 [patent_app_country] => US [patent_app_date] => 2020-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 99330 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16925068 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16598351 [patent_doc_number] => 20210024882 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-28 [patent_title] => COMPOSITIONS AND METHODS FOR ENHANCING CELL CULTURE [patent_app_type] => utility [patent_app_number] => 16/921626 [patent_app_country] => US [patent_app_date] => 2020-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22656 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16921626 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17792109 [patent_doc_number] => 20220251200 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => EXTRACELLULAR VESICLES TARGETING T CELLS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/624524 [patent_app_country] => US [patent_app_date] => 2020-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47043 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -80 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17624524 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17913264 [patent_doc_number] => 20220315659 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-06 [patent_title] => Multivalent FZD and WNT Binding Molecules and Uses Thereof [patent_app_type] => utility [patent_app_number] => 17/596485 [patent_app_country] => US [patent_app_date] => 2020-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33504 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17596485 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16435723 [patent_doc_number] => 20200353048 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-12 [patent_title] => METHOD OF TREATING A METABOLIC DISORDER OF THE LIVER [patent_app_type] => utility [patent_app_number] => 16/878534 [patent_app_country] => US [patent_app_date] => 2020-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36352 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16878534 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17719130 [patent_doc_number] => 20220211849 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => SIALYLATED GLYCOPROTEINS [patent_app_type] => utility [patent_app_number] => 17/602156 [patent_app_country] => US [patent_app_date] => 2020-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6165 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17602156 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17640530 [patent_doc_number] => 20220168268 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-02 [patent_title] => SMALL-MOLECULE INHIBITOR OF PD-1/PD-L1, PHARMACEUTICAL COMPOSITION THEREOF WITH PD-L1 ANTIBODY, AND APPLICATION OF SAME [patent_app_type] => utility [patent_app_number] => 17/441410 [patent_app_country] => US [patent_app_date] => 2020-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28775 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17441410 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17595387 [patent_doc_number] => 20220144960 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => CD30-BINDING MOIETIES, CHIMERIC ANTIGEN RECEPTORS, AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/312497 [patent_app_country] => US [patent_app_date] => 2019-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 70521 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -65 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17312497 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18683939 [patent_doc_number] => 11779649 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-10 [patent_title] => Antibodies to PMEL17 and conjugates thereof [patent_app_type] => utility [patent_app_number] => 16/718866 [patent_app_country] => US [patent_app_date] => 2019-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 53 [patent_no_of_words] => 57933 [patent_no_of_claims] => 55 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16718866 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16175509 [patent_doc_number] => 20200222477 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-16 [patent_title] => Method to Curtail the Progression of Non-Muscle Invasive Bladder Cancer To Muscle-Invasive Cancer [patent_app_type] => utility [patent_app_number] => 16/702782 [patent_app_country] => US [patent_app_date] => 2019-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3800 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16702782 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15927775 [patent_doc_number] => 20200155521 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-21 [patent_title] => PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/686517 [patent_app_country] => US [patent_app_date] => 2019-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60835 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16686517 [rel_patent_id] =>[rel_patent_doc_number] =>)